Katherine Weiland is a registered patent agent. Katherine’s practice is focused on freedom-to-operate and validity investigations, infringement analysis, due diligence, and patent procurement in the pharmaceutical, biotechnical and biochemical sciences. She has an extensive biotechnology background in the areas of microbiology, virology, cancer and apoptosis.
Katherine concentrates on portfolio management and patent prosecution relating to a variety of technologies involving pharmaceuticals, pharmaceutical formulations, and biotechnological inventions, including food systems, plant utility, DNA and peptide sequences, vaccines, immunostimulants, bacterial toxin materials and methods, analgesics, anti-thrombotics, screening/ diagnostic materials and methods, transdermal hormone replacement therapies, drug delivery formulations (e.g., controlled and delayed-release oral dosage forms).
Prior to joining Hueschen and Sage, Katherine worked as a molecular biologist/biochemist in human drug discovery research at Pfizer (and legacy companies Pharmacia, Pharmacia and Upjohn Company, The Upjohn Company) 1989 to 2003, and at Hoffmann-La Roche, 1985-1989.
Katherine is a co-inventor on U.S. Patent No. 6,833,248, has presented her work at scientific conferences and is an author/co-author on published abstracts, a book chapter, and numerous peer-reviewed scientific publications.
- Northern Illinois University, MS, Microbial Genetics, 1984
- Northern Illinois University, BS, Biology, minor in Chemistry, 1981
- Registered Patent Agent, US Patent and Trademark Office, 2005